Mode
Text Size
Log in / Sign up
N/A N=90 Randomized Single-blind Treatment

AVAPS-AE Efficacy Study

Obesity Hypoventilation Syndrome

Enrolled (actual)
90
Serious AEs
6.3%
Results posted
Apr 2019
Primary outcome: Primary: Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2) — 47.1; 51.8; 50.7; 40.7 mmHg

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
AVAPS-AE Mode of Therapy (Device); Respironics OnmiLab BiPAP S mode (Device); Respironics OmniLab Advanced CPAP mode (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Philips Respironics
Primary completion
May 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2)
47.1; 51.8; 50.7; 40.7; 47.4; 40.8
SECONDARY
Daytime Partial Pressure of Oxygen in Arterial Blood(Pa02)
62.8; 56.9; 62.6; 65.0; 58.7; 66.2
SECONDARY
Apnea Hypopnea Index (AHI)
84.5; 67.7; 85.4; 16.1; 22.4; 30.1
SECONDARY
Epworth Sleepiness Scale
14.9; 12.0; 11.5; 9.8; 8.1; 5.9
SECONDARY
Severe Respiratory Insufficiency Questionnaire (SRIQ)
52.0; 53.4; 60.0; 61.0; 64.8; 69.7
SECONDARY
Ventilator Adherence - Average Hours
4.8; 5.2; 6.6
SECONDARY
Ventilator Adherence - Days Used
5.3; 5.3; 6.9
SECONDARY
Actigraphy
SECONDARY
Room Air Sp02 Assessment Via Pulse Oximetry
92.5; 90.6; 92.9; 94.6; 90.1; 94.1
SECONDARY
Nocturnal Transcutaneous Capnography (TcC02)
SECONDARY
Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study) - Duration
28.4; 24.6; 18.9; 10.0; 13.1; 10.1
SECONDARY
Duration and Quality of Sleep and Sleepiness (Derived From Sleep Study) - Sleep Efficiency
74.4; 64.5; 74.6; 86.8; 71.4; 74.4
SECONDARY
Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study)- Arousal and Awakening Indices
68.2; 66.0; 71.4; 19.4; 23.0; 21.3
SECONDARY
Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study)- Nocturnal O2 Saturation
84.2; 81.6; 81.1; 92.7; 93.3; 94.5
SECONDARY
Reaction Time (Psychomotor Vigilance Test-PVT)
3987.13; 4752.75; 4523.25; 2978.89; 5681.83; 6705.20
SECONDARY
Number of Participants With Need for Continued Oxygen Supplementation
1; 4; 0; 0; 2; 1

Summary

The purpose of this study is to evaluate the feasibility of using of the Average Volume Assured Pressure Support (AVAPS-AE) mode versus Continuous Positive Airway Pressure (CPAP) and bilevel pressure support ventilation (PSV) modes of ventilation in patients diagnosed with Obesity Hypoventilation syndrome (OHS). The investigators believe the use of the AVAPS-AE mode of ventilation after 6 weeks will yield daytime gas exchange values which are equivalent or no worse when compared to using CPAP and bilevel PSV modes of ventilation in the OHS population.

Eligibility Criteria

Inclusion Criteria

  • Age greater than or equal to 18 years of age; less than or equal to 70 years of age
  • Diagnosis of Obesity Hypoventilation Syndrome via a diagnostic sleep study in the past 3 months but have not initiated therapy
  • BMI greater than or equal to 30 kg/m2
  • Daytime PaCO2 greater than or equal to 45 mmHg
  • Apnea Hypopnea index (AHI) > 5
  • Daytime pH > 7.35
  • Forced Expiratory Volume at 1 second / forced vital capacity (FEV1/FVC) > 70%

Exclusion Criteria

  • Acutely ill, medically complicated or who are medically stable, or as otherwise determined by the investigator
  • Respiratory alkalosis (pH > 7.45), per investigator discretion
  • Emergency admissions on chronic respiratory failure
  • Hospitalization for respiratory exacerbation < 6 weeks prior to screening visit
  • Participants in whom PAP therapy is otherwise medically contraindicated
  • Impaired upper airway function. For example, obstruction due to infections(laryngitis, epiglottis), craniofacial malformations, tumors, uvulopalatopharyngoplasty, presence of tracheostomy, or bilateral vocal cord palsy that does not allow tolerance of Non-invasive positive pressure ventilation (NPPV)
  • Facial trauma, burns, surgery or anatomical abnormalities interfering with mask fit.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01368614). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search